retatrutide clinical trial phase retatrutide stage Results After 40: Realistic Timelines & FAQ Today, we shared new data

The Phase 3 program includes trials in obesity, type 2 diabetes, and metabolic dysfunction-associated steatohepatitis (MASH, formerly known as NASH)

Scientific Mechanism: The Tri-Agonist Effect Retatrutide (LY3437943) is a single peptide molecule that exhibits agonist activity at the Glucagon-Like Peptide-1 (GLP-1), Glucose-Dependent Insulinotropic Polypeptide (GIP), and Glucagon (GCG) receptors

Not a replacement for approved medical therapies

Clinical trial data reveal that bromocriptine mesylate at doses up to 4.8 mg per day was not associated with a different rate of all-cause adverse events compared with placebo

This subjectively seems to help, although it's annoying that twice the injections means twice the redness and swelling

Heart rate increase Phase 2 data showed a mean heart rate increase of around 6.7 beats per minute on the 12 mg dose, peaking at about week 24 and declining slightly thereafter